Journal articles: 'Advanced drug delivery systems'

1

Alallam, Batoul, Hazem Choukaife, Salma Seyam, Vuanghao Lim, and Mulham Alfatama. "Advanced Drug Delivery Systems for Renal Disorders." Gels 9, no. 2 (February 1, 2023): 115. http://dx.doi.org/10.3390/gels9020115.

Full text

Abstract:

Kidney disease management and treatment are currently causing a substantial global burden. The kidneys are the most important organs in the human urinary system, selectively filtering blood and metabolic waste into urine via the renal glomerulus. Based on charge and/or molecule size, the glomerular filtration apparatus acts as a barrier to therapeutic substances. Therefore, drug distribution to the kidneys is challenging, resulting in therapy failure in a variety of renal illnesses. Hence, different approaches to improve drug delivery across the glomerulus filtration barrier are being investigated. Nanotechnology in medicine has the potential to have a significant impact on human health, from illness prevention to diagnosis and treatment. Nanomaterials with various physicochemical properties, including size, charge, surface and shape, with unique biological attributes, such as low cytotoxicity, high cellular internalization and controllable biodistribution and pharmacokinetics, have demonstrated promising potential in renal therapy. Different types of nanosystems have been employed to deliver drugs to the kidneys. This review highlights the features of the nanomaterials, including the nanoparticles and corresponding hydrogels, in overcoming various barriers of drug delivery to the kidneys. The most common delivery sites and strategies of kidney-targeted drug delivery systems are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

2

Riahi, Reza, Ali Tamayol, Seyed Ali Mousavi Shaegh, Amir M. Ghaemmaghami, Mehmet R. Dokmeci, and Ali Khademhosseini. "Microfluidics for advanced drug delivery systems." Current Opinion in Chemical Engineering 7 (February 2015): 101–12. http://dx.doi.org/10.1016/j.coche.2014.12.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bordbar-Khiabani, Aydin, and Michael Gasik. "Smart Hydrogels for Advanced Drug Delivery Systems." International Journal of Molecular Sciences 23, no. 7 (March 27, 2022): 3665. http://dx.doi.org/10.3390/ijms23073665.

Full text

Abstract:

Since the last few decades, the development of smart hydrogels, which can respond to stimuli and adapt their responses based on external cues from their environments, has become a thriving research frontier in the biomedical engineering field. Nowadays, drug delivery systems have received great attention and smart hydrogels can be potentially used in these systems due to their high stability, physicochemical properties, and biocompatibility. Smart hydrogels can change their hydrophilicity, swelling ability, physical properties, and molecules permeability, influenced by external stimuli such as pH, temperature, electrical and magnetic fields, light, and the biomolecules’ concentration, thus resulting in the controlled release of the loaded drugs. Herein, this review encompasses the latest investigations in the field of stimuli-responsive drug-loaded hydrogels and our contribution to this matter.

APA, Harvard, Vancouver, ISO, and other styles

4

Arshad, Shumaila, Ali Aun, and Muhammad Uzair Yousaf. "Drug Delivery System in Pakistan: A Review." Research in Pharmacy and Health Sciences 2, no. 3 (August 15, 2016): 174–78. http://dx.doi.org/10.32463/rphs.2016.v02i03.35.

Full text

Abstract:

Drug Delivery systems are the means by which drug molecules are delivered to sites of action within the body.There are several pharmaceutical dosage forms (delivery Systems) available in Pakistan that is being used in different health care centers. Both conventional and advance dosage forms are used now days depending upon the condition of the patient, the disease state and available resources. But unfortunately Pakistan is a way behind in the field of technology among the other developing and developed countries in the world. There are few private setups which are well equipped with high class technology that caters the need of advanced drug delivery system in Pakistan. Mostly advanced drug dosage forms are imported from the other countries, thus it costs Pakistan a lot. In the present study Drug Delivery Systems in Pakistan is thoroughly studied and represented according to the generations of drug delivery system.

APA, Harvard, Vancouver, ISO, and other styles

5

Gorantla, Srividya, Tejashree Waghule, Vamshi Krishna Rapalli, Prem Prakash Singh, Sunil Kumar Dubey, Ranendra Narayan Saha, and Gautam Singhvi. "Advanced Hydrogels Based Drug Delivery Systems for Ophthalmic Delivery." Recent Patents on Drug Delivery & Formulation 13, no. 4 (April 29, 2020): 291–300. http://dx.doi.org/10.2174/1872211314666200108094851.

Full text

Abstract:

Hydrogels are aqueous gels composed of cross-linked networks of hydrophilic polymers. Stimuli-responsive based hydrogels have gained focus over the past 20 years for treating ophthalmic diseases. Different stimuli-responsive mechanisms are involved in forming polymer hydrogel networks, including change in temperature, pH, ions, and others including light, thrombin, pressure, antigen, and glucose-responsive. Incorporation of nanocarriers with these smart stimuli-responsive drug delivery systems that can extend the duration of action by increasing ocular bioavailability and reducing the dosing frequency. This review will focus on the hydrogel drug delivery systems highlighting the gelling mechanisms and emerging stimuli-responsive hydrogels from preformed gels, nanogels, and the role of advanced 3D printed hydrogels in vision-threatening diseases like age-related macular degeneration and retinitis pigmentosa. It also provides insight into the limitations of hydrogels along with the safety and biocompatibility of the hydrogel drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

6

Tang, Lu, Jing Li, Qingqing Zhao, Ting Pan, Hui Zhong, and Wei Wang. "Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery." Pharmaceutics 13, no. 8 (July 27, 2021): 1151. http://dx.doi.org/10.3390/pharmaceutics13081151.

Full text

Abstract:

The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.

APA, Harvard, Vancouver, ISO, and other styles

7

Shen, Haosheng, Nikhil Aggarwal, Kwok Soon Wun, Yung Seng Lee, In Young Hwang, and Matthew Wook Chang. "Engineered microbial systems for advanced drug delivery." Advanced Drug Delivery Reviews 187 (August 2022): 114364. http://dx.doi.org/10.1016/j.addr.2022.114364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Karimi, Mahdi, Sajad Bahrami, Soodeh Baghaee Ravari, Parham Sahandi Zangabad, Hamed Mirshekari, Mahnaz Bozorgomid, Somayeh Shahreza, Masume Sori, and Michael R. Hamblin. "Albumin nanostructures as advanced drug delivery systems." Expert Opinion on Drug Delivery 13, no. 11 (June 3, 2016): 1609–23. http://dx.doi.org/10.1080/17425247.2016.1193149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Greineder, Colin F., Melissa D. Howard, Ronald Carnemolla, Douglas B. Cines, and Vladimir R. Muzykantov. "Advanced drug delivery systems for antithrombotic agents." Blood 122, no. 9 (August 29, 2013): 1565–75. http://dx.doi.org/10.1182/blood-2013-03-453498.

Full text

Abstract:

Abstract Despite continued achievements in antithrombotic pharmacotherapy, difficulties remain in managing patients at high risk for both thrombosis and hemorrhage. Utility of antithrombotic agents (ATAs) in these settings is restricted by inadequate pharmacokinetics and narrow therapeutic indices. Use of advanced drug delivery systems (ADDSs) may help to circumvent these problems. Various nanocarriers, affinity ligands, and polymer coatings provide ADDSs that have the potential to help optimize ATA pharmacokinetics, target drug delivery to sites of thrombosis, and sense pathologic changes in the vascular microenvironment, such as altered hemodynamic forces, expression of inflammatory markers, and structural differences between mature hemostatic and growing pathological clots. Delivery of ATAs using biomimetic synthetic carriers, host blood cells, and recombinant fusion proteins that are activated preferentially at sites of thrombus development has shown promising outcomes in preclinical models. Further development and translation of ADDSs that spare hemostatic fibrin clots hold promise for extending the utility of ATAs in the management of acute thrombotic disorders through rapid, transient, and targeted thromboprophylaxis. If the potential benefit of this technology is to be realized, a systematic and concerted effort is required to develop clinical trials and translate the use of ADDSs to the clinical arena.

APA, Harvard, Vancouver, ISO, and other styles

10

Sung, Hsing-Wen, and Zhuang Liu. "Advanced Drug Delivery Systems for Therapeutic Applications." Advanced Healthcare Materials 3, no. 8 (August 2014): 1130–32. http://dx.doi.org/10.1002/adhm.201400323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Rodríguez, Diego A., and Pieter Vader. "Extracellular Vesicle-Based Hybrid Systems for Advanced Drug Delivery." Pharmaceutics 14, no. 2 (January 23, 2022): 267. http://dx.doi.org/10.3390/pharmaceutics14020267.

Full text

Abstract:

The continuous technological advancement of nanomedicine has enabled the development of novel vehicles for the effective delivery of therapeutic substances. Synthetic drug delivery systems are nano-sized carriers made from various materials that can be designed to deliver therapeutic cargoes to cells or tissues. However, rapid clearance by the immune system and the poor targeting profile of synthetic drug delivery systems are examples of the pressing obstacles faced in nanomedicine, which have directed the field toward the development of alternative strategies. Extracellular vesicles (EVs) are nanoscale particles enclosed by a protein-rich lipid bilayer; they are released by cells and are considered to be important mediators of intercellular communication. Owing to their natural composition, EVs have been suggested to exhibit good biocompatibility and to possess homing properties to specific cell types. Combining EVs with synthetic nanoparticles by defined hybridization steps gives rise to a novel potential drug delivery tool, i.e., EV-based hybrid systems. These novel therapeutic vehicles exhibit potential advantageous features as compared to synthetic drug delivery systems such as enhanced cellular uptake and cargo delivery, immuno-evasive properties, capability of crossing biological barriers, and tissue targeting profile. Here, we provide an overview of the various strategies practiced to produce EV-based hybrid systems and elucidate those advantageous features obtained by synthetic drug delivery systems upon hybridization with EVs.

APA, Harvard, Vancouver, ISO, and other styles

12

Zhong, Hao, Ging Chan, Yuanjia Hu, Hao Hu, and Defang Ouyang. "A Comprehensive Map of FDA-Approved Pharmaceutical Products." Pharmaceutics 10, no. 4 (December 6, 2018): 263. http://dx.doi.org/10.3390/pharmaceutics10040263.

Full text

Abstract:

With the increasing research and development (R&D) difficulty of new molecular entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention. This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the technical barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems. According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technology barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly technical barriers had less competition and greater market potential. Our study provides a comprehensive insight into FDA-approved products and deep analysis of the technical barriers for advanced drug delivery systems. In the future, the R&D of new molecular entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.

APA, Harvard, Vancouver, ISO, and other styles

13

Zhang, Zhengwei. "The Effectiveness of Combined Drug Delivery Systems." Journal of Drug Delivery and Therapeutics 9, no. 1-s (February 15, 2019): 377–80. http://dx.doi.org/10.22270/jddt.v9i1-s.2266.

Full text

Abstract:

Treatment of tumors with nanoparticles and combined drugs tend to turn effective as it can sustain for a longer time in the recipient’s body and also improve the impact. The conjugates that have proven to have high cytotoxicity are suggested in this report. Pegylation is an advanced drug delivery system that maximizes the immunity of the patient and helps in the correct targeting of the affected cells. Keywords: Tumors, Nanoparticles, Drug targeting

APA, Harvard, Vancouver, ISO, and other styles

14

Begum, Gousia S., and Mustafa D. "An Advanced Review on Resealed Erythrocytes." Asian Journal of Pharmaceutical Research and Development 7, no. 6 (December 15, 2019): 55–61. http://dx.doi.org/10.22270/ajprd.v7i6.606.

Full text

Abstract:

Now a days there are numerous applications have been proposed for the use of resealed erythrocytes as carrier for drugs, enzyme replacement therapy etc. Until other carrier systems come of age, resealed erythrocytes technology will remain an active field for the further research. The use of resealed erythrocytes shows potential for a safe and effective delivery of various bioactive molecules for effective targeting. In coming future, erythrocyte based drug delivery system with their capability to afford controlled and site specific drug delivery have been developed for disease management. Erythrocyte carriers are “Nano devices in the field of Nanotechnology”. A large amount of valuable work is needed so as to utilize the potentials of erythrocytes in passive as well as active targeting of drugs in diseases like cancer. At present erythrocytes are most effective carriers in novel drug delivery systems considering their tremendous potential. Hence the present article is reviewed about method of drug loading, evaluation and applications of RSE.

APA, Harvard, Vancouver, ISO, and other styles

15

Lohani, Alka, Garima Singh, Shiv Sankar Bhattacharya, and Anurag Verma. "Interpenetrating Polymer Networks as Innovative Drug Delivery Systems." Journal of Drug Delivery 2014 (May 14, 2014): 1–11. http://dx.doi.org/10.1155/2014/583612.

Full text

Abstract:

Polymers have always been valuable excipients in conventional dosage forms, also have shown excellent performance into the parenteral arena, and are now capable of offering advanced and sophisticated functions such as controlled drug release and drug targeting. Advances in polymer science have led to the development of several novel drug delivery systems. Interpenetrating polymer networks (IPNs) have shown superior performances over the conventional individual polymers and, consequently, the ranges of applications have grown rapidly for such class of materials. The advanced properties of IPNs like swelling capacity, stability, biocompatibility, nontoxicity and biodegradability have attracted considerable attention in pharmaceutical field especially in delivering bioactive molecules to the target site. In the past few years various research reports on the IPN based delivery systems showed that these carriers have emerged as a novel carrier in controlled drug delivery. The present review encompasses IPNs, their types, method of synthesis, factors which affects the morphology of IPNs, extensively studied IPN based drug delivery systems, and some natural polymers widely used for IPNs.

APA, Harvard, Vancouver, ISO, and other styles

16

Winnicka, Katarzyna. "Special Issue: Advanced Materials in Drug Release and Drug Delivery Systems." Materials 14, no. 4 (February 23, 2021): 1042. http://dx.doi.org/10.3390/ma14041042.

Full text

Abstract:

Development of new drug molecules is costly and requires longitudinal, wide-ranging studies; therefore, designing advanced pharmaceutical formulations for existing and well-known drugs seems to be an attractive device for the pharmaceutical industry [...]

APA, Harvard, Vancouver, ISO, and other styles

17

Maniruzzaman, Mohammed, and Ali Nokhodchi. "Advanced Implantable Drug Delivery Systems via Continuous Manufacturing." Critical Reviews™ in Therapeutic Drug Carrier Systems 33, no. 6 (2016): 569–89. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.2016018537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Chudiwal, Vijay, and Sadhana Shahi. "Patent Perspective of Advanced Gastroretentive Drug Delivery Systems." Research Journal of Pharmaceutical Dosage Forms and Technology 8, no. 1 (2016): 15. http://dx.doi.org/10.5958/0975-4377.2016.00003.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ibrić, Svetlana, Jelena Parojčić, and Aleš Mrhar. "From smart materials to advanced drug delivery systems." International Journal of Pharmaceutics 533, no. 2 (November 2017): 323. http://dx.doi.org/10.1016/j.ijpharm.2017.08.105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Nurhidayah, Deti, Ali Maruf, Xiaojuan Zhang, Xiaoling Liao, Wei Wu, and Guixue Wang. "Advanced drug-delivery systems: mechanoresponsive nanoplatforms applicable in atherosclerosis management." Nanomedicine 14, no. 23 (December 2019): 3105–22. http://dx.doi.org/10.2217/nnm-2019-0172.

Full text

Abstract:

Nanoplatforms have been used extensively as advanced carriers to enhance the effectiveness of drug delivery, mostly through passive aggregation provided by the enhanced permeability and retention effect. Mechanical stimuli provide a robust strategy to bolster drug delivery performance by increasing the accumulation of nanoplatforms at the lesion sites, facilitating on-demand cargo release and providing theranostic aims. In this review, we focus on recent advances of mechanoresponsive nanoplatforms that can accomplish targeted drug delivery, and subsequent drug release, under specific stimuli, either endogenous (shear stress) or exogenous (magnetic field and ultrasound), to synergistically combat atherosclerosis at the molecular level.

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Tian-Zuo, Xin-Xin Liu, Si-Yu Wang, Yan Liu, Xin-Yang Pan, Jing-Jie Wang, and Kai-Hui Nan. "Engineering Advanced Drug Delivery Systems for Dry Eye: A Review." Bioengineering 10, no. 1 (December 31, 2022): 53. http://dx.doi.org/10.3390/bioengineering10010053.

Full text

Abstract:

Dry eye disease (DED) is a widespread and frequently reported multifactorial ocular disease that not only causes ocular discomfort but also damages the cornea and conjunctiva. At present, topical administration is the most common treatment modality for DED. Due to the existence of multiple biological barriers, instilled drugs generally exhibit short action times and poor penetration on the ocular surface. To resolve these issues, several advanced drug delivery systems have been proposed. This review discusses new dosage forms of drugs for the treatment of DED in terms of their characteristics and advantages. Innovative formulations that are currently available in the market and under clinical investigation are elaborated. Meanwhile, their deficiencies are discussed. It is envisioned that the flourishing of advanced drug delivery systems will lead to improved management of DED in the near future.

APA, Harvard, Vancouver, ISO, and other styles

22

Cegielska, Olga, and Paweł Sajkiewicz. "Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review." Polymers 11, no. 11 (October 24, 2019): 1742. http://dx.doi.org/10.3390/polym11111742.

Full text

Abstract:

Each year, new glaucoma drug delivery systems are developed. Due to the chronic nature of the disease, it requires the inconvenient daily administration of medications. As a result of their elution from the eye surface and penetration to the bloodstream through undesired permeation routes, the bioavailability of active compounds is low, and systemic side effects occur. Despite numerous publications on glaucoma drug carriers of controlled drug release kinetics, only part of them consider drug permeation routes and, thus, carriers’ location, as an important factor affecting drug delivery. In this paper, we try to demonstrate the importance of the delivery proximal to glaucoma drug targets. The targeted delivery can significantly improve drug bioavailability, reduce side effects, and increase patients’ compliance compared to both commercial and scientifically developed formulations that can spread over the eye surface or stay in contact with conjunctival sac. We present a selection of glaucoma drug carriers intended to be placed on cornea or injected into the aqueous humor and that have been made by advanced materials using hi-tech forming methods, allowing for effective and convenient sustained antiglaucoma drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

23

Villarreal-Gómez, Luis Jesús, Aracely Serrano-Medina, Erick José Torres-Martínez, Graciela Lizeth Perez-González, and José Manuel Cornejo-Bravo. "Polymeric advanced delivery systems for antineoplasic drugs: doxorubicin and 5-fluorouracil." e-Polymers 18, no. 4 (July 26, 2018): 359–72. http://dx.doi.org/10.1515/epoly-2017-0202.

Full text

Abstract:

AbstractConventional pharmaceuticals generally display the inability to transport active ingredients directly to specific regions of the body, amongst some of their main limitations. The distribution of the drugs in the circulatory system may lead to undesired toxicity, and therefore, adverse reactions. To address this situation, a selective transport of drugs is required, that is, releasing drugs specifically to the site of action in appropriate concentrations and in the right time. To achieve this goal, it is necessary to develop delivery systems that respond to several features, such as low toxicity, optimum properties for the transport and release of the drug, as well as a long half-life in the body. This feature paper critically provides an overview of different strategies of controlled drug release for two model antineoplasic drugs, i.e. doxorubicin (DOX) and 5-fluorouracil (5-FU). Any of the presented strategies for drug release possess advantages and disadvantages, and the selection of the strategy used will depend on the targeted tissue and nature of the drug.

APA, Harvard, Vancouver, ISO, and other styles

24

Kong, Xiangqi, Yi Liu, Xueyan Huang, Shuai Huang, Feng Gao, Pengfei Rong, Shengwang Zhang, Kexiang Zhang, and Wenbin Zeng. "Cancer Therapy Based on Smart Drug Delivery with Advanced Nanoparticles." Anti-Cancer Agents in Medicinal Chemistry 19, no. 6 (July 10, 2019): 720–30. http://dx.doi.org/10.2174/1871520619666190212124944.

Full text

Abstract:

Background: Cancer, as one of the most dangerous disease, causes millions of deaths every year. The main reason is the absence of an effective and thorough treatment. Drug delivery systems have significantly reduced the side-effect of chemotherapy. Combined with nanotechnology, smart drug delivery systems including many different nanoparticles can reduce the side-effect of chemotherapy better than traditional drug delivery systems. Methods: In this article, we will describe in detail the different kinds of nanoparticles and their mechanisms emphasizing the triggering factors in drug delivery. Besides, the application of smart drug delivery systems in imaging will be introduced. Results: Combined with nanotechnology, smart drug delivery systems including many different nanoparticles can reduce the side-effect of chemotherapy better than traditional drug delivery systems. Conclusion: Despite considerable progress in nanoparticle research over the past decade, such as smart drug delivery systems for the treatment of cancer, molecular imaging probes and the like. The range of nanoparticles used in multifunction systems for imaging and drug delivery continues to grow and we expect this dilatation to continue. But to make nanoparticles truly a series of clinical products to complement and replace current tools, constant exploration efforts and time are required. Overall, the future looks really bright.

APA, Harvard, Vancouver, ISO, and other styles

25

Bodoki, Andreea E., Bogdan-C. Iacob, Elena Dinte, Oliviu Vostinaru, Ovidiu Samoila, and Ede Bodoki. "Perspectives of Molecularly Imprinted Polymer-Based Drug Delivery Systems in Ocular Therapy." Polymers 13, no. 21 (October 23, 2021): 3649. http://dx.doi.org/10.3390/polym13213649.

Full text

Abstract:

Although the human eye is an easily accessible sensory organ, it remains a challenge for drug administration due to the presence of several anatomical and physiological barriers which limit the access of drugs to its internal structures. Molecular imprinting technology may be considered the avant-garde approach in advanced drug delivery applications and, in particular, in ocular therapy. In fact, molecularly imprinted polymers hold the promise to compensate for the current shortcomings of the available arsenal of drug delivery systems intended for ocular therapy. The present manuscript aims to review the recent advances, the current challenges and most importantly to raise awareness on the underexplored potential and future perspectives of molecularly imprinted polymer-based drug delivery systems intended for the treatment of eye diseases.

APA, Harvard, Vancouver, ISO, and other styles

26

Kotta, Sabna, Hibah Mubarak Aldawsari, Shaimaa M. Badr-Eldin, Anroop B. Nair, and Kamal YT. "Progress in Polymeric Micelles for Drug Delivery Applications." Pharmaceutics 14, no. 8 (August 5, 2022): 1636. http://dx.doi.org/10.3390/pharmaceutics14081636.

Full text

Abstract:

Polymeric micelles (PMs) have made significant progress in drug delivery applications. A robust core–shell structure, kinetic stability and the inherent ability to solubilize hydrophobic drugs are the highlights of PMs. This review presents the recent advances and understandings of PMs with a focus on the latest drug delivery applications. The types, methods of preparation and characterization of PMs are described along with their applications in oral, parenteral, transdermal, intranasal and other drug delivery systems. The applications of PMs for tumor-targeted delivery have been provided special attention. The safety, quality and stability of PMs in relation to drug delivery are also provided. In addition, advanced polymeric systems and special PMs are also reviewed. The in vitro and in vivo stability assessment of PMs and recent understandings in this area are provided. The patented PMs and clinical trials on PMs for drug delivery applications are considered indicators of their tremendous future applications. Overall, PMs can help overcome many unresolved issues in drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

27

Kim, Min, Seung-Hae Kwon, Jung Choi, and Aeju Lee. "A Promising Biocompatible Platform: Lipid-Based and Bio-Inspired Smart Drug Delivery Systems for Cancer Therapy." International Journal of Molecular Sciences 19, no. 12 (December 4, 2018): 3859. http://dx.doi.org/10.3390/ijms19123859.

Full text

Abstract:

Designing new drug delivery systems (DDSs) for safer cancer therapy during pre-clinical and clinical applications still constitutes a considerable challenge, despite advances made in related fields. Lipid-based drug delivery systems (LBDDSs) have emerged as biocompatible candidates that overcome many biological obstacles. In particular, a combination of the merits of lipid carriers and functional polymers has maximized drug delivery efficiency. Functionalization of LBDDSs enables the accumulation of anti-cancer drugs at target destinations, which means they are more effective at controlled drug release in tumor microenvironments (TMEs). This review highlights the various types of ligands used to achieve tumor-specific delivery and discusses the strategies used to achieve the effective release of drugs in TMEs and not into healthy tissues. Moreover, innovative recent designs of LBDDSs are also described. These smart systems offer great potential for more advanced cancer therapies that address the challenges posed in this research area.

APA, Harvard, Vancouver, ISO, and other styles

28

Mohsen, Amira Mohamed. "Nanotechnology Advanced Strategies for the Management of Diabetes Mellitus." Current Drug Targets 20, no. 10 (July 12, 2019): 995–1007. http://dx.doi.org/10.2174/1389450120666190307101642.

Full text

Abstract:

Background:Medications currently available for the management of diabetes mellitus are inconvenient and have some limitations. Thus, investigations for novel approaches are needed to deliver and target antidiabetics safely to the site of action.Objective:The present review emphasizes the limitations of conventional antidiabetics and provides the recent progresses of nanotechnology in the treatment of diabetes mellitus with a special highlight on the novel nanocarriers methodologies employed as antidiabetic drug delivery systems.Methods:The potential nanocarriers employed for the treatment of diabetes comprise liposomes, niosomes, self-nanoemulsifying drug delivery systems, polymeric nanoparticles, gold nanoparticles, dendrimers and micelles. Herbal nanomedicine has also emerged to be a promising way for adequate delivery of herbal compounds. Other nanotechnology approaches involve the usage of oral insulin, inhalable insulin, artificial pancreas, and nanopump.Results:Nanocarriers have proved to lead a successful delivery of antidiabetic medications, aiming at drug targeting for enhanced efficacy and safety.Conclusion:These innovative generations of drug delivery systems have important benefits over conventionally existing ones. The future of nanotechnology in the management of diabetes is still open with several prospects and will be of pronounced significance.

APA, Harvard, Vancouver, ISO, and other styles

29

Varshi, Reena, Vikas Jain, and Pradeep Pal. "A review on Advanced approaches and polymers used in gastroretentive drug delivery systems." Journal of Drug Delivery and Therapeutics 12, no. 4 (July 15, 2022): 181–85. http://dx.doi.org/10.22270/jddt.v12i4.5422.

Full text

Abstract:

Insufficient pharmacokinetic characteristics may be associated with the widespread use of oral dosage forms in the treatment of disease. In some cases, the drug is barely soluble; in others, the formulation's rapid transit through the gastrointestinal tract (GIT) makes it difficult to achieve therapeutic levels in body; in addition, some drugs must act locally due to a gastric pathology, but they remain in the stomach for only a short time. Numerous studies have focused on the development of formulations that are capable of enhancing all of these characteristics and extending the stomach residence duration. The prolonged stomach retention duration afforded by gastroretentive controlled drug delivery devices increases the therapeutic efficacy of many orally administered drugs. In the present investigation, we reviewed the advanced methods and polymers used to develop effective gastroretentive drug delivery systems. These methods include swelling and expansion, mucoadhesive, high density, low density, ion exchange, raft forming, magnetic, and floating drug delivery systems. The development of gastroretentive devices involves a broad array of polymeric materials. This work intends to expedite the development of innovative methods by offering a comprehensive understanding of unique gastroretentive approaches along with the polymeric materials utilised in the fabrication of gastroretentive drug delivery systems for oral drug delivery. Keywords: Gastroretentive; mucoadhesive; floating; raft forming system; mucoadhesive; swellable.

APA, Harvard, Vancouver, ISO, and other styles

30

Iravani, Siavash, and Rajender S. Varma. "Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases." Molecules 27, no. 18 (September 9, 2022): 5843. http://dx.doi.org/10.3390/molecules27185843.

Full text

Abstract:

Advanced drug delivery micro- and nanosystems have been widely explored due to their appealing specificity/selectivity, biodegradability, biocompatibility, and low toxicity. They can be applied for the targeted delivery of pharmaceuticals, with the benefits of good biocompatibility/stability, non-immunogenicity, large surface area, high drug loading capacity, and low leakage of drugs. Cardiovascular diseases, as one of the primary mortalities cause worldwide with significant impacts on the quality of patients’ life, comprise a variety of heart and circulatory system pathologies, such as peripheral vascular diseases, myocardial infarction, heart failure, and coronary artery diseases. Designing novel micro- and nanosystems with suitable targeting properties and smart release behaviors can help circumvent crucial challenges of the tolerability, low stability, high toxicity, and possible side- and off-target effects of conventional drug delivery routes. To overcome different challenging issues, namely physiological barriers, low efficiency of drugs, and possible adverse side effects, various biomaterials-mediated drug delivery systems have been formulated with reduced toxicity, improved pharmacokinetics, high bioavailability, sustained release behavior, and enhanced therapeutic efficacy for targeted therapy of cardiovascular diseases. Despite the existing drug delivery systems encompassing a variety of biomaterials for treating cardiovascular diseases, the number of formulations currently approved for clinical use is limited due to the regulatory and experimental obstacles. Herein, the most recent advancements in drug delivery micro- and nanosystems designed from different biomaterials for the treatment of cardiovascular diseases are deliberated, with a focus on the important challenges and future perspectives.

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, Kelly L. "Advances in Drug Delivery Systems." Journal of Membrane Science 34, no. 1 (November 1987): 121–22. http://dx.doi.org/10.1016/s0376-7388(00)80024-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Herbig, Scott M. "Advances in drug delivery systems." Journal of Membrane Science 43, no. 1 (January 1989): 121–22. http://dx.doi.org/10.1016/s0376-7388(00)82357-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Nishiyama, Nobuhiro, and Kazunori Kataoka. "Design of intelligent drug delivery systems for advanced medicine." Drug Delivery System 26, no. 1 (2011): 29–36. http://dx.doi.org/10.2745/dds.26.29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Vecsernyés, Miklós. "New Insights into Advanced Drug Delivery and Absorption Systems." Scientia Pharmaceutica 88, no. 2 (April 10, 2020): 20. http://dx.doi.org/10.3390/scipharm88020020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Wang, Shuo, Keqin Han, Shuhao Ma, Xiaojing Qi, Ling Guo, and Xuejin Li. "Blood cells as supercarrier systems for advanced drug delivery." Medicine in Drug Discovery 13 (March 2022): 100119. http://dx.doi.org/10.1016/j.medidd.2021.100119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bansal, Shyam S., Mehak Goel, Farrukh Aqil, Manicka V. Vadhanam, and Ramesh C. Gupta. "Advanced Drug Delivery Systems of Curcumin for Cancer Chemoprevention." Cancer Prevention Research 4, no. 8 (May 5, 2011): 1158–71. http://dx.doi.org/10.1158/1940-6207.capr-10-0006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ding, B. S. "Advanced Drug Delivery Systems That Target The Vascular Endothelium." Molecular Interventions 6, no. 2 (April 1, 2006): 98–112. http://dx.doi.org/10.1124/mi.6.2.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Misak, Heath E., Ramazan Asmatulu, Janani S. Gopu, Ka-Poh Man, Nora M. Zacharias, Paul H. Wooley, and Shang-You Yang. "Albumin-based nanocomposite spheres for advanced drug delivery systems." Biotechnology Journal 9, no. 1 (October 23, 2013): 163–70. http://dx.doi.org/10.1002/biot.201300150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lengyel, Miléna, Nikolett Kállai-Szabó, Vince Antal, András József Laki, and István Antal. "Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery." Scientia Pharmaceutica 87, no. 3 (August 9, 2019): 20. http://dx.doi.org/10.3390/scipharm87030020.

Full text

Abstract:

Microparticles, microspheres, and microcapsules are widely used constituents of multiparticulate drug delivery systems, offering both therapeutic and technological advantages. Microparticles are generally in the 1–1000 µm size range, serve as multiunit drug delivery systems with well-defined physiological and pharmacokinetic benefits in order to improve the effectiveness, tolerability, and patient compliance. This paper reviews their evolution, significance, and formulation factors (excipients and procedures), as well as their most important practical applications (inhaled insulin, liposomal preparations). The article presents the most important structures of microparticles (microspheres, microcapsules, coated pellets, etc.), interpreted with microscopic images too. The most significant production processes (spray drying, extrusion, coacervation, freeze-drying, microfluidics), the drug release mechanisms, and the commonly used excipients, the characterization, and the novel drug delivery systems (microbubbles, microsponges), as well as the preparations used in therapy are discussed in detail.

APA, Harvard, Vancouver, ISO, and other styles

40

Singh, Satya Prakash, Anup Kumar Sirbaiya, and Anuradha Mishra. "Bioinspired Smart Nanosystems in Advanced Therapeutic Applications." Pharmaceutical Nanotechnology 7, no. 3 (August 6, 2019): 246–56. http://dx.doi.org/10.2174/2211738507666190425122822.

Full text

Abstract:

Background: Nanoparticle technologies used for human administration must be designed to interact with a living host environment. The idea about bioinspired smart drug delivery carriers includes the development of biocompatible nanomaterials which can be further loaded with the drug for specific targeted drug delivery applications. Objective: Biosmart nanosystems are used for several applications in the delivery of drugs and pharmaceuticals for their therapeutic applications like biological markers, diagnostic purposes such as imaging applications and also for gene therapy. Thus, the bioinspired nanocarriers are capable of carrying biologically active molecules to the target sites. This bioinspired nanosystem constitutes of lipids, polymers and biomaterials which utilizes various responsive sensors for targeted drug delivery systems. However, external conditions such as heat, light, magnetic or electric field and ultrasounds, along with temperature, altered pH and ionic strength can affect the bioinspired smart nanosystem for drug delivery. Conclusion: The present review focuses on challenges for the development of bioinspired smart nanocarriers for the management of various disorders.

APA, Harvard, Vancouver, ISO, and other styles

41

Tian, Bo, Evan Bilsbury, Sean Doherty, Sean Teebagy, Emma Wood, Wenqi Su, Guangping Gao, and Haijiang Lin. "Ocular Drug Delivery: Advancements and Innovations." Pharmaceutics 14, no. 9 (September 13, 2022): 1931. http://dx.doi.org/10.3390/pharmaceutics14091931.

Full text

Abstract:

Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.

APA, Harvard, Vancouver, ISO, and other styles

42

Gao, Ge, Minjun Ahn, Won-Woo Cho, Byoung-Soo Kim, and Dong-Woo Cho. "3D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery." Pharmaceutics 13, no. 9 (August 31, 2021): 1373. http://dx.doi.org/10.3390/pharmaceutics13091373.

Full text

Abstract:

Advances in three-dimensional (3D) printing techniques and the development of tailored biomaterials have facilitated the precise fabrication of biological components and complex 3D geometrics over the past few decades. Moreover, the notable growth of 3D printing has facilitated pharmaceutical applications, enabling the development of customized drug screening and drug delivery systems for individual patients, breaking away from conventional approaches that primarily rely on transgenic animal experiments and mass production. This review provides an extensive overview of 3D printing research applied to drug screening and drug delivery systems that represent pharmaceutical applications. We classify several elements required by each application for advanced pharmaceutical techniques and briefly describe state-of-the-art 3D printing technology consisting of cells, bioinks, and printing strategies that satisfy requirements. Furthermore, we discuss the limitations of traditional approaches by providing concrete examples of drug screening (organoid, organ-on-a-chip, and tissue/organ equivalent) and drug delivery systems (oral/vaginal/rectal and transdermal/surgical drug delivery), followed by the introduction of recent pharmaceutical investigations using 3D printing-based strategies to overcome these challenges.

APA, Harvard, Vancouver, ISO, and other styles

43

Wadhwa, Abishek, Vashish Mathura, and Shaila Angela Lewis. "EMERGING NOVEL NANOPHARMACEUTICALS FOR DRUG DELIVERY." Asian Journal of Pharmaceutical and Clinical Research 11, no. 7 (July 7, 2018): 35. http://dx.doi.org/10.22159/ajpcr.2018.v11i7.25149.

Full text

Abstract:

Nanotechnology is an area of growing public interest. Employing nanotechnology in the field of drug delivery has led to the advent of nanopharmaceuticals. Nanopharmaceuticals are bound to surmount various obstacles that the field of pharmacy is currently facing by offering various advantages thereby, a promising potential to formulate advanced medicines with fewer adverse effects. Extensive research is in place, thus instigating the development of novel drug delivery systems, such as carbon nanotubes, nanosponges, nano wafers, and nanofibers, to name a few. Since their inception, these nanopharmaceuticals have advanced significantly regarding their preparation strategy and scope of applications. This article aims to review the merits, limitations, and scope of these aforementioned delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

44

Sultan, Adnan Ahmed, Aditya Pratap Singh, Abhipriya Rajan, and Anupam Tiwary. "Advancement of Biomimetic Nanoparticles for Targeted Drug Delivery." International Journal of Chemical and Environmental Sciences 3, no. 2 (January 3, 2022): 7–41. http://dx.doi.org/10.15864/ijcaes.3201.

Full text

Abstract:

There has been an increasing requirement for more efficient and less iatrogenic therapies for drug delivery, encouraging researches to develop new vectors that ensure targeted delivery of drugs and other therapeutic agents in medicine. Traditional synthetic drug vectors which include polymer and lipid particles are not preferred for clinical applications due to their high cytotoxicity, greater immunogenicity and low cell membrane penetrability. On the other hand, natural particulates ranging from pathogens to mammalian cells are specially optimized for in vivo functions and possess features desirable for drug delivery vectors. Biomimetics involves exploiting biological organisms, cells and molecules or deriving inspiration from them. The Biomimetic Nanoparticles have ushered a new generation of drug carriers, attracting researchers because of their excellent biocompatibility, biodistribution, low chances of recognition and removal by the immune system. Their ability to mimic the bio-structure and function of the biological system makes them reliable drug delivery vectors especially for disease targeting. The advanced biotechnology tools used for engineering synthetic and natural derived nano-systems along with better understanding of biological systems, have enabled researchers to apply these ideas to the delivery of drugs, small interfering RNA, proteins and other therapeutic agents. This review summarizes recent advances in biomimetic nanoparticles used for targeted drug delivery in medicine, obtained by processing synthetic materials using biomimetics. The challenges of biomimetic delivery systems and future directions are also discussed and proposed herein.

APA, Harvard, Vancouver, ISO, and other styles

45

Kumar, S. Pradeep, and Prathibha D. "Current Approaches and Pharmaceutical Applications of Colloidosome Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 5, no. 4 (February 28, 2013): 1832–40. http://dx.doi.org/10.37285/ijpsn.2012.5.4.2.

Full text

Abstract:

Recently a number of lipid based systems like lipospheres, liposomes, niosomes, ethosomes, and transferosomes have been developed. The purpose of this review article on colloidosome drug delivery was to compile the focus on the types, properties, fabrication techniques, characterization and stability of colloidosomes. This system also solves the problem of insolubility, instability, rapid degradation and is widely used in specialized areas like protein delivery, gene delivery, targeting to the brain and tumor targeting. In a series of vascular systems, colloidosome represents an advanced tool in drug delivery. Colloidosomes are an emerging vesicular system in drug delivery. Vesicular drug delivery reduces the cost of therapy by improved bioavailability of medication, especially in the case of poorly soluble drugs. Colloidosomes have a great encapsulation efficacy with a wide control over size, permeability, mechanical strength and compatibility.

APA, Harvard, Vancouver, ISO, and other styles

46

Kumar, Lalit, Shivani Verma, Mehakjot Singh, Tammana Chalotra, and Puneet Utreja. "Advanced Drug Delivery Systems for Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs: A Review." Current Drug Delivery 15, no. 8 (August 16, 2018): 1087–99. http://dx.doi.org/10.2174/1567201815666180605114131.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bruni, Natascia, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi, and Franco Dosio. "Cannabinoid Delivery Systems for Pain and Inflammation Treatment." Molecules 23, no. 10 (September 27, 2018): 2478. http://dx.doi.org/10.3390/molecules23102478.

Full text

Abstract:

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.

APA, Harvard, Vancouver, ISO, and other styles

48

Ng, Jaryl Chen Koon, Daniel Wee Yee Toong, Valerie Ow, Su Yin Chaw, Hanwei Toh, Philip En Hou Wong, Subbu Venkatraman, et al. "Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation." Nanomedicine 17, no. 5 (February 2022): 325–47. http://dx.doi.org/10.2217/nnm-2021-0288.

Full text

Abstract:

Drug-delivery systems in cardiovascular applications regularly include the use of drug-eluting stents and drug-coated balloons to ensure sufficient drug transfer and efficacy in the treatment of cardiovascular diseases. In addition to the delivery of antiproliferative drugs, the use of growth factors, genetic materials, hormones and signaling molecules has led to the development of different nanoencapsulation techniques for targeted drug delivery. The review will cover drug delivery and coating mechanisms in current drug-eluting stents and drug-coated balloons, novel innovations in drug-eluting stent technologies and drug encapsulation in nanocarriers for delivery in vascular diseases. Newer technologies and advances in nanoencapsulation techniques, such as the use of liposomes, nanogels and layer-by-layer coating to deliver therapeutics in the cardiovascular space, will be highlighted.

APA, Harvard, Vancouver, ISO, and other styles

49

Maurya, Priyanka, Saman Fatma, Durgesh Sharma, Jai Narayan Mishra, and Ashutosh Kushwaha. "OCULAR DRUG DELIVERY SYSTEMS: AN OVERVIEW." IJRDO-Journal of Applied Science 8, no. 11 (November 23, 2022): 26–30. http://dx.doi.org/10.53555/as.v8i11.5439.

Full text

Abstract:

The treatment for the ophthalmic diseases are topical route because of the various ocular barrier. Ocular drug delivery systems are considered as major challenges by today’s pharmacologist and formulation scientist. Topical eye drop is the most convenient and patient compliant route of drug administration, especially for the treatment of anterior segment diseases. tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery techniques, which may surpass these barriers and maintain drug levels in tissues. There are many eye ailments which affected to eye and one can loss the eye sight also. Therefore, many ophthalmic drug delivery systems are available. These are classified as conventional and non- conventional (newer) drug delivery systems. Most commonly available ophthalmic preparations are eye drops and ointments about 70% of the eye dosage formulations in market. So overcome to these problems newer pharmaceutical ophthalmic formulation such as in-situ gel, nanoparticle, liposome, nanosuspension, microemulsion, intophoresis and ocular inserts have been developed in last three decades increase the bioavailability of the drug as a sustained and controlled manner.

APA, Harvard, Vancouver, ISO, and other styles

50

Ma, Zhiyuan, Baicheng Li, Jie Peng, and Dan Gao. "Recent Development of Drug Delivery Systems through Microfluidics: From Synthesis to Evaluation." Pharmaceutics 14, no. 2 (February 17, 2022): 434. http://dx.doi.org/10.3390/pharmaceutics14020434.

Full text

Abstract:

Conventional drug administration usually faces the problems of degradation and rapid excretion when crossing many biological barriers, leading to only a small amount of drugs arriving at pathological sites. Therapeutic drugs delivered by drug delivery systems to the target sites in a controlled manner greatly enhance drug efficacy, bioavailability, and pharmacokinetics with minimal side effects. Due to the distinct advantages of microfluidic techniques, microfluidic setups provide a powerful tool for controlled synthesis of drug delivery systems, precisely controlled drug release, and real-time observation of drug delivery to the desired location at the desired rate. In this review, we present an overview of recent advances in the preparation of nano drug delivery systems and carrier-free drug delivery microfluidic systems, as well as the construction of in vitro models on-a-chip for drug efficiency evaluation of drug delivery systems. We firstly introduce the synthesis of nano drug delivery systems, including liposomes, polymers, and inorganic compounds, followed by detailed descriptions of the carrier-free drug delivery system, including micro-reservoir and microneedle drug delivery systems. Finally, we discuss in vitro models developed on microfluidic devices for the evaluation of drug delivery systems, such as the blood–brain barrier model, vascular model, small intestine model, and so on. The opportunities and challenges of the applications of microfluidic platforms in drug delivery systems, as well as their clinical applications, are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Advanced drug delivery systems'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles